A collaboration between Leeds Teaching Hospitals NHS Trust and global medical technology company Becton Dickinson (BD) has yielded a product that can simplify the process of identifying cancer cells. BD Intrasure allows scientists to study intracellular markers by flow cytometry, a technique commonly used in the research of leukaemia and lymphoma.
Some markers are on the surface of cancer cells but most are inside the cells. Currently, the intracellular markers are usually tested on solid tissue samples, which take a day or two to process. Performing the research using flow cytometry cuts this time down to a couple of hours.
The BD Intrasure reagents support this key research tool by ensuring that cancer cells are opened up to reveal the intracellular markers while being kept in a suitable morphological state.
www.bd.com